Stanley Satz, Ph.D.Chief Scientific Officer at Advanced Innovative Partners, Inc.
Stanley Satz, Ph.D. is a former defense contractor and educator who comes from the ‘death sciences’ to the ‘life sciences’. He is a scientist and radiation physicist with more than 25 years of research and development and “milspec” production experience, manufacturing and marketing radioactive materials and instrumentation for medical and industrial use. Satz founded Bio-Nucleonics after leaving Mount Sinai Medical Center of Miami Beach and a Professorship at the University of Miami. He is Chairman and Chief Scientific Officer of Advanced Innovative Partners, Inc.
Satz developed a U.S. Food and Drug Administration approved therapeutic radiopharmaceutical for treatment of bone pain arising from metastatic breast, prostate and lung cancer, Strontium-89, in addition to several drugs for management of pediatric cancers, currently in clinical trials. He has authored numerous journal articles and has five awarded U.S. patents.
Satz is a co-founder of Boca Raton, Florida based Advanced Imaging Projects, LLC (AiP), a clinical stage specialty biopharmaceutical company focused on the discovery, development and commercialization of molecular medicines for prevention, diagnosis and treatment of oncological, neurological and infectious disorders. He concentrates his scientific and technical leadership on small molecules for pediatric diseases.
Satz has worked for the World Health Organization in Latin America. He founded Bio-Nucleonics after leaving Mount Sinai Medical Center of Miami Beach and a Professorship the University of Miami. A graduate of the University of Miami, he is former Chairman of the Scientific Advisory Board of Florida Atlantic University, is on the Board of the U.S. Industry Coalition, and a publicly traded biotechnology company. In addition, he is Chairman of the G-8 International Working Group on Nanosafety and Nanosecurity.
He and his team is advancing several diagnostic and therapeutic radiopharmaceuticals in clinic for molecular nuclear medicine. ‘Theranostic’ combinations have the potential to change patient management and outcomes in multiple diseases. Among the indications being investigated are HER2+ breast cancer, prostate cancer and several pediatric diseases with high unmet need including neuroblastoma acute lymphoblastic leukemia, glioblastoma, diffuse intrinsic pontine glioma, atypical teratoid rhabdoid tumor and pancreatoblastoma. The group is also focused on the application of artificial intelligence and deep leaining in oncology and nuclear medicine, developing potentially game changing radiopharmaceuticals for positron emission tomography imaging and tumor targeted therapy, opening a new era in precision medicine.
In July 2021, Satz was selected to represent the U.S. Government and to be the keynote speak at a conference organized by the International Atomic Energy Agency on radiopharmaceuticals and alpha emitters.